NCT04731155View on ClinicalTrials.gov

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Early PCSK9 Inhibitor on Ventricular Remodling
Interventions
DRUG

PCSK9 inhibitor （Alirocumab）plus standard medications

PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI

DRUG

standard medications

standard medications was giving to subjects according guidelines

Trial Locations (2)

Unknown

RECRUITING

Tongren Hospital, Shanghai, Shanghai

RECRUITING

Shanghai tenth people's hospital, Shanghai

All Listed Sponsors
lead

Shanghai Tong Ren Hospital

OTHER